In the present study, we report the validation of the CellDx tumor profiling assay, which includes NGS profiling of gene alterations (SNAs, CNAs, Indels, Gene Fusion and TMB), Capillary electrophoresis (CE) for Microsatellite instability (BAT-25, BAT-26, NR-21, NR-24, and MONO-27), IHC for detection of PD-L1 (28–8 and 22C3) expression and IHC for MMR status (MLH1, MSH2, MSH6, PMS2). This evidence concerns the gene CD274 and neoplasm.